since I have no particular expertise in the medica
Post# of 9144
(Total Views: 464)
Posted On: 03/11/2020 4:31:07 AM
since I have no particular expertise in the medical field I dont know how disparate, segmented or isolated the medical world is- the articles i've read indicate there is considerable discontinuity at least geographically re new possible vaccines etc
in my field the discontinuity re new good things is also very high
startups are little known outside their small community and although NNLX is technically not a startup re its flatpack petri dishes it still is re the N assay
NNLX has participated in various govt programs,conversations /programs with other medical companies and programs like the Bill and Melinda Gates Africa TB
initiative but in a world of too much information and too little wisdom how does a tiny startup get its point across?
NNLX has tried- as NNLX noted in its recent communications with stock holders-see below
Does the Gates foundation have a built-in process as they should -given what they do- to search out and employ such medical solutions- yet they are probably unaware of NNLX's N assay, which was not part of the Africa TB initiative
part of the problem is isolation and non-communication among different specialized groups, as I've discussed many times,plus only relatively small subsegments of the medical community apparently having the necessary understanding or discernment to recognize the value of various new methodologies
https://www.marketwatch.com/story/these-nine-...=home-page
e.g.,the above story does not mention other companies which are known and searchable via google to be working on a solution, including at least one w a vaccine within possibly 8-10 weeks
Posted On: 02/28/2020 11:32:38 AM
Posted By: mitstevfel
Response to Coronavirus Queries both International and US
The Company continues to receive calls inquiring about Coronavirus (COVID-19) testing capabilities.
While we believe our technology could be used to develop a rapid test for the Coronavirus, based upon preliminary development work done for detection of proteins associated with Ebola in 2014, we do not have the resources to pursue development of a Coronavirus rapid test. There are a small number of BioSafety Level 4 labs in the US (4+/-) where development work on dangerous viruses can be done and their calendars are booked months to years in advance with daily costs that can run into tens of thousands of dollars. The Coronavirus may be a short-lived phenomenon that is no longer an issue within a few months; there are other tests that exist that may deliver reliable results in a few hours or a day, and while a test we develop may potentially deliver results in minutes, it may not be viewed as worthwhile in a cost:benefit analysis by various agencies or institutions.
In conclusion, we are fully committed to our current work on Urinary Tract and Yeast Infections rapid detection development utilizing a unique screening test and our N-Assay modified ELISA process.
Posted On: 01/31/2020 3:04:22 PM
Posted By: Eudius
Update:
NanoLogix Incorporated
Response to Coronavirus Questions From Shareholders
Given a number of queries from shareholders asking if our technology could be used for rapid detection of the current Coronavirus originating in Wuhan, China we felt the following response is necessary:
Based upon positive preliminary research performed in 2014 with the N-Assay on Ebola virus protein markers, we believe both the N-Assay and the new Screening test currently under development have the potential for use in rapid detection of the Coronavirus. That said, given our focus on refinement of both the Screening Test and N-Assay Rapid Diagnostic for Urinary Tract and other bacterial and yeast infections, our limited resources as a small biotechnology company, along with the demonstrated historical lack of interest from potential partners and funders during the Ebola outbreak ,[emphasis added] we currently have no intention of individually pursuing development for Coronavirus detection without the assistance and cooperation of well-funded entities. ee
in my field the discontinuity re new good things is also very high
startups are little known outside their small community and although NNLX is technically not a startup re its flatpack petri dishes it still is re the N assay
NNLX has participated in various govt programs,conversations /programs with other medical companies and programs like the Bill and Melinda Gates Africa TB
initiative but in a world of too much information and too little wisdom how does a tiny startup get its point across?
NNLX has tried- as NNLX noted in its recent communications with stock holders-see below
Does the Gates foundation have a built-in process as they should -given what they do- to search out and employ such medical solutions- yet they are probably unaware of NNLX's N assay, which was not part of the Africa TB initiative
part of the problem is isolation and non-communication among different specialized groups, as I've discussed many times,plus only relatively small subsegments of the medical community apparently having the necessary understanding or discernment to recognize the value of various new methodologies
https://www.marketwatch.com/story/these-nine-...=home-page
e.g.,the above story does not mention other companies which are known and searchable via google to be working on a solution, including at least one w a vaccine within possibly 8-10 weeks
Posted On: 02/28/2020 11:32:38 AM
Posted By: mitstevfel
Response to Coronavirus Queries both International and US
The Company continues to receive calls inquiring about Coronavirus (COVID-19) testing capabilities.
While we believe our technology could be used to develop a rapid test for the Coronavirus, based upon preliminary development work done for detection of proteins associated with Ebola in 2014, we do not have the resources to pursue development of a Coronavirus rapid test. There are a small number of BioSafety Level 4 labs in the US (4+/-) where development work on dangerous viruses can be done and their calendars are booked months to years in advance with daily costs that can run into tens of thousands of dollars. The Coronavirus may be a short-lived phenomenon that is no longer an issue within a few months; there are other tests that exist that may deliver reliable results in a few hours or a day, and while a test we develop may potentially deliver results in minutes, it may not be viewed as worthwhile in a cost:benefit analysis by various agencies or institutions.
In conclusion, we are fully committed to our current work on Urinary Tract and Yeast Infections rapid detection development utilizing a unique screening test and our N-Assay modified ELISA process.
Posted On: 01/31/2020 3:04:22 PM
Posted By: Eudius
Update:
NanoLogix Incorporated
Response to Coronavirus Questions From Shareholders
Given a number of queries from shareholders asking if our technology could be used for rapid detection of the current Coronavirus originating in Wuhan, China we felt the following response is necessary:
Based upon positive preliminary research performed in 2014 with the N-Assay on Ebola virus protein markers, we believe both the N-Assay and the new Screening test currently under development have the potential for use in rapid detection of the Coronavirus. That said, given our focus on refinement of both the Screening Test and N-Assay Rapid Diagnostic for Urinary Tract and other bacterial and yeast infections, our limited resources as a small biotechnology company, along with the demonstrated historical lack of interest from potential partners and funders during the Ebola outbreak ,[emphasis added] we currently have no intention of individually pursuing development for Coronavirus detection without the assistance and cooperation of well-funded entities. ee
(0)
(0)